Ranitidine bismuth citrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ranitidine bismuth citrate and what is the scope of patent protection?
Ranitidine bismuth citrate
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for ranitidine bismuth citrate
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 20 |
Clinical Trials: | 5 |
Patent Applications: | 306 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ranitidine bismuth citrate at DailyMed |
Recent Clinical Trials for ranitidine bismuth citrate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Alphacait, LLC | Phase 2 |
Federal University of São Paulo | Phase 4 |
US Patents and Regulatory Information for ranitidine bismuth citrate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |